Advertisement
| egfr mutation targeted therapy: Successes and Limitations of Targeted Cancer Therapy S. Peters, R.A. Stahel, 2014-02-19 The treatment of patients with advanced malignancies has undergone remarkable change in the last few years. While in the past decisions about systemic therapy were largely based on the performance status of a patient, oncologists today also take into account the pathological and molecular characteristics of the patient’s tumor. Targeting specific molecular pathways important for tumorigenesis has become the preferred way of treatment for many types of malignancies. With these advances come new challenges including the optimization of therapy, recognizing and dealing with side effects and, importantly, the development of resistance. This book provides an up-to-date overview of the advances and limitations of targeted therapy for several tumor entities including breast cancer, colon cancer, gastrointestinal stromal tumors, lung cancer, melanoma, ovarian cancer and renal cell carcinoma. Written by over a dozen internationally renowned scientists, the book is suitable for advanced students, postdoctoral researchers, scientists and clinicians who wish to update their knowledge of the latest approaches to targeted cancer therapies. |
| egfr mutation targeted therapy: Molecular Pathology of Lung Cancer Philip T. Cagle, Timothy Craig Allen, Mary Beth Beasley, Lucian R. Chirieac, Sanja Dacic, Alain C. Borczuk, Keith M. Kerr, 2012-06-14 As with other books in the Molecular Pathology Library Series, Molecular Pathology of Lung Cancer bridges the gap between the molecular specialist and the clinical practitioner, including the surgical pathologist who now has a key role in decisions regarding molecular targeted therapy for lung cancer. Molecular Pathology of Lung Cancer provides the latest information and current insights into the molecular basis for lung cancer, including precursor and preinvasive lesions, molecular diagnosis, molecular targeted therapy, molecular prognosis, molecular radiology and related fields for lung cancer generally and for the specific cell types. As many fundamental concepts about lung cancer have undergone revision in only the past few years, this book will likely be the first to comprehensively cover the new molecular pathology of lung cancer. It provides a foundation in this field for pathologists, medical oncologists, radiation oncologists, thoracic surgeons, thoracic radiologists and their trainees, physician assistants, and nursing staff. |
| egfr mutation targeted therapy: IASLC Atlas of ALK and ROS1 Testing in Lung Cancer Ming Sound Tsao, Fred R. Hirsch, Yasushi Yatabe, 2016-12-04 The IASLC Atlas of ALK and ROS1 Testing in Lung Cancer is a resource designed to help pathologists, laboratory scientists, and practicing physicians better understand the background, protocol, and interpretation of results of ALK and ROS1 testing for patients with advanced non-small cell lung cancer. |
| egfr mutation targeted therapy: Lung Cancer Karen L. Reckamp, 2016-08-17 This book describes the molecular mechanisms of lung cancer development and progression that determine therapeutic interventions in the era of genomics, when the rapid evolution in lung cancer diagnosis and treatment necessitates critical review of new results to integrate advances into practice. The text opens with background and emerging information regarding the molecular biology of lung cancer pathogenesis. Updated results regarding lung cancer prevention and screening are discussed, followed by chapters on diagnostic techniques and pathological evaluation. This leads on to a detailed presentation of treatment modalities, from surgery and radiation therapy to standard chemotherapy and targeted agents. The coverage includes resistance to therapy and the emergence of immunotherapy for lung cancer; in addition, the current evidence in respect of small cell lung cancer is summarized. The book presents insights from experts across disciplines to emphasize the importance of collaborative care. Advances in our understanding of issues in geriatric oncology and palliative care complete the comprehensive discussion of lung cancer. |
| egfr mutation targeted therapy: Cancer Signaling Christoph Wagener, Carol Stocking, Oliver Müller, 2016-08-12 Cancer, which has become the second-most prevalent health issue globally, is essentially a malfunction of cell signaling. Understanding how the intricate signaling networks of cells and tissues allow cancer to thrive - and how they can be turned into potent weapons against it - is the key to managing cancer in the clinic and improving the outcome of cancer therapies. In their ground-breaking textbook, the authors provide a compelling story of how cancer works on the molecular level, and how targeted therapies using kinase inhibitors and other modulators of signaling pathways can contain and eventually cure it. The first part of the book gives an introduction into the cell and molecular biology of cancer, focusing on the key mechanisms of cancer formation. The second part of the book introduces the main signaling transduction mechanisms responsible for carcinogenesis and compares their function in healthy versus cancer cells. In contrast to the complexity of its topic, the text is easy to read. 32 specially prepared teaching videos on key concepts and pathways in cancer signaling are available online for users of the print edition and have been integrated into the text in the enhanced e-book edition. |
| egfr mutation targeted therapy: Pulmonary Adenocarcinoma: Approaches to Treatment Leora Horn, 2018-10-24 Get a quick, expert overview of the latest treatment and management approaches for adenocarcinoma of the lung, including novel therapeutics in immunotherapy and targeted therapies. This practical title, edited by Dr. Leora Horn, offers succinct coverage of clinically-focused topics and guidelines, making it an ideal resource for practicing and trainee oncologists and other members of the cancer care team. - Discusses surgical approaches, molecular testing, adjuvant therapy, first- and second-line therapy, and much more. - Helps you translate current research and literature into practical information for daily practice. - Consolidates today's available information on this timely topic into one convenient resource. |
| egfr mutation targeted therapy: Outcomes Assessment in Cancer Joseph Lipscomb, Carolyn C. Gotay, Claire Snyder, 2011-08-18 The U.S. National Cancer Institute established the Cancer Outcomes Measurement Working Group in 2001 to evaluate measurements of the important and diverse impacts of cancer on individuals and populations. The findings and recommendations of the working group's 35 internationally recognized members provide alternative approaches for comprehensively measuring the burden of cancer and the effectiveness of preventive and therapeutic interventions. |
| egfr mutation targeted therapy: Introduction to Basics of Pharmacology and Toxicology Abialbon Paul, Nishanthi Anandabaskar, Jayanthi Mathaiyan, Gerard Marshall Raj, 2021-03-13 This book explains the pharmacological relationships between the various systems in the human body. It offers a comprehensive overview of the pharmacology concerning the autonomic, central, and peripheral nervous systems. Presenting up-to-date information on chemical mediators and their significance, it highlights the therapeutic aspects of several diseases affecting the cardiovascular, renal, respiratory, gastrointestinal, endocrinal, and hematopoietic systems. The book also includes drug therapy for microbial and neoplastic diseases. It also comprises sections on immunopharmacology, dermatological, and ocular pharmacology providing valuable insights into these emerging and recent topics. Covering the diverse groups of drugs acting on different systems, the book reviews their actions, clinical uses, adverse effects, interactions, and subcellular mechanisms of action. It is divided into 11 parts, subdivided into several chapters that evaluate the basic pharmacological principles that govern the different types of body systems. This book is intended for academicians, researchers, and clinicians in industry and academic institutions in pharmaceutical, pharmacological sciences, pharmacy, medical sciences, physiology, neurosciences, biochemistry, molecular biology and other allied health sciences. |
| egfr mutation targeted therapy: Guide to Targeted Therapies: EGFR mutations in NSCLC Federico Cappuzzo, 2014-09-25 Guide to Targeted Therapies: EGFR Mutations in NSCLC is a speedy and up-to-date review, which discusses EGFR mutations, testing methods and technology, current and emerging therapies, and resources that clinicians can provide to their patients. Busy healthcare professionals who want a quick review of EGFR gene mutations as well as a summary of current therapies will benefit from this succinct guide. |
| egfr mutation targeted therapy: Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy , 2018-11-21 Tyrosine Kinase Inhibitors as Sensitizing Agents for Chemotherapy, the fourth volume in the Cancer Sensitizing Agents for Chemotherapy Series, focuses on strategic combination therapies that involve a variety of tyrosine kinase inhibitors working together to overcome multi-drug resistance in cancer cells. The book discusses several tyrosine kinase inhibitors that have been used as sensitizing agents, such as EGFR, BCR-ABL, ALK and BRAF. In each chapter, readers will find comprehensive knowledge on the inhibitor and its action, including its biochemical, genetic, and molecular mechanisms' emphases. This book is a valuable source for oncologists, cancer researchers and those interested in applying new sensitizing agents to their research in clinical practice and in trials. - Summarizes the sensitizing role of some tyrosine kinase inhibitors in existing research - Brings recent findings in several cancer types, both experimental and clinically, with a particular emphases on underlying biochemical, genetic, and molecular mechanisms - Provides an updated and comprehensive knowledge regarding the field of combinational cancer treatment |
| egfr mutation targeted therapy: Successful Drug Discovery, Volume 3 János Fischer, Christian Klein, Wayne E. Childers, 2018-06-05 With its focus on drugs so recently introduced that they have yet to be found in any other textbooks or general references, the information and insight found here makes this a genuinely unique handbook and reference. Following the successful approach of the previous volumes in the series, inventors and primary developers of successful drugs from both industry and academia tell the story of the drug's discovery and describe the sometimes twisted route from the first drug candidate molecule to the final marketed drug. The 11 case studies selected describe recent drugs ranging across many therapeutic fields and provide a representative cross-section of present-day drug developments. Backed by plenty of data and chemical information, the insight and experience of today's top drug creators makes this one of the most useful training manuals that a junior medicinal chemist may hope to find. The International Union of Pure and Applied Chemistry has endorsed and sponsored this project because of its high educational merit. |
| egfr mutation targeted therapy: Pancreatic Cancer Douglas B. Evans, Peter W.T. Pisters, James L. Abruzzese, 2002 The MD Anderson Solid Tumor Oncology series presents cutting-edge surgical treatment and medical therapy for specific sites. This volume, Pancreatic Cancer, addresses epidemiology and molecular biology, inherited syndromes, staging, surgical techniques, multimodality therapy, and emerging therapies. The individual chapters focus on narrow, specific topics to produce a reference work of value to those interested in pancreatic cancer from a clinical and translational research perspective. A must-have for surgical oncologists and general surgeons. |
| egfr mutation targeted therapy: Dermatologic Principles and Practice in Oncology Mario E. Lacouture, 2013-11-26 The first book focusing specifically on frequent and frequently disabling side effects involving the skin, hair and nails in cancer patients According to the World Health Organization, there are approximately thirty million people living with a diagnosis of cancer – the majority of whom will receive surgery, systemic therapy, and/or radiation, and who will suffer from dermatologic adverse events. Dermatologists and oncologists are only beginning to grapple with these events, which pose serious quality-of-life issues with so many patients, and will become more prevalent as survival rates improve, thanks in part to new cancer treatments and drug regimens. Concentrating on a topic that has only been briefly touched upon by other texts, this book offers a focused perspective on the clinical presentation, underlying pathophysiologic mechanisms, and management of skin, hair, and nail conditions for oncologists, dermatologists, and allied practitioners. Dermatologic Principles and Practice in Oncology: Conditions of the Skin, Hair, and Nails in Cancer Patients: • Covers in detail the dermatologic adverse events of oncologic therapies, clinical presentations, and treatment recommendations • Enables dermatologists and other practitioners to significantly improve the care of patients with cancer • Addresses the dermatologic adverse events of cancer therapies used globally, of which a large number are found in developing countries • Emphasizes prophylactic measures – based on treatments used and type of cancer – to prevent the appearance of adverse events • Provides built-in discussions on patient education for practical counseling during therapies • Offers rapid-reference sections on topical dermatology drugs The first book to present dermatologic conditions in cancer patients and survivors in a uniform and in-depth manner, Dermatologic Principles and Practice in Oncology is ideal for oncologists, oncology nurses, and dermatologists who wish to take better care of those with adverse skin, hair, and nail conditions. |
| egfr mutation targeted therapy: Clinical Trials in Oncology, Third Edition Stephanie Green, Jacqueline Benedetti, Angela Smith, John Crowley, 2012-05-09 The third edition of the bestselling Clinical Trials in Oncology provides a concise, nontechnical, and thoroughly up-to-date review of methods and issues related to cancer clinical trials. The authors emphasize the importance of proper study design, analysis, and data management and identify the pitfalls inherent in these processes. In addition, the book has been restructured to have separate chapters and expanded discussions on general clinical trials issues, and issues specific to Phases I, II, and III. New sections cover innovations in Phase I designs, randomized Phase II designs, and overcoming the challenges of array data. Although this book focuses on cancer trials, the same issues and concepts are important in any clinical setting. As always, the authors use clear, lucid prose and a multitude of real-world examples to convey the principles of successful trials without the need for a strong statistics or mathematics background. Armed with Clinical Trials in Oncology, Third Edition, clinicians and statisticians can avoid the many hazards that can jeopardize the success of a trial. |
| egfr mutation targeted therapy: Central Nervous System Metastases Manmeet Ahluwalia, Philippe Metellus, Riccardo Soffietti, 2019-11-05 This book provides a comprehensive overview of brain metastases, from the molecular biology aspects to therapeutic management and perspectives. Due to the increasing incidence of these tumors and the urgent need to effectively control brain metastatic diseases in these patients, new therapeutic strategies have emerged in recent years. The volume discusses all these innovative approaches combined with new surgical techniques (fluorescence, functional mapping, integrated navigation), novel radiation therapy techniques (stereotactic radiosurgery) and new systemic treatment approaches such as targeted- and immunotherapy. These combination strategies represent a new therapeutic model in brain metastatic patients in which each medical practitioner (neurosurgeon, neurologist, medical oncologist, radiation oncologist) plays a pivotal role in defining the optimal treatment in a multidisciplinary approach. Written by recognized experts in the field, this book is a valuable tool for neurosurgeons, neuro-oncologists, neuroradiologists, medical oncologists, radiation oncologists, cognitive therapists, basic scientists and students working in the area of brain tumors. |
| egfr mutation targeted therapy: Geriatric Oncology Martine Extermann, 2020-01-30 This book is intended as a comprehensive resource for clinicians and researchers seeking in-depth information on geriatric oncology. The coverage encompasses epidemiology, the biology and (patho)physiology of aging and cancer, geriatric assessment and management, hematologic malignancies, solid tumors, issues in patient care, and research methods. Since cancer is a disease of aging and people are living longer, most cancer patients are now aged 70 and older. Yet the more we age, the more diverse we become in terms of our health, biologic fitness, and cancer behavior. Typically, however, general oncology clinical trials address only a selected healthier and younger population of patients. Geriatric oncology is the area of oncology that addresses these issues but while a wealth of knowledge has been accumulated, information is often difficult to retrieve or insufficiently detailed. The SpringerReference program, in which this book is published, offers an ideal format for overcoming these limitations since it combines thorough coverage with access to living editions constantly updated chapter by chapter via a dynamic peer-review process, ensuring that information remains current and pertinent. |
| egfr mutation targeted therapy: Histological Typing of Lung and Pleural Tumours W.D. Travis, T.V. Colby, B. Corrin, Y. Shimosato, E. Brambilla, 2012-12-06 with contributions by Pathologists from 14 Countries |
| egfr mutation targeted therapy: Immune Checkpoint Inhibitors in Cancer Fumito Ito, Marc Ernstoff, 2018-09-03 Get a quick, expert overview of the latest clinical information and guidelines for cancer checkpoint inhibitors and their implications for specific types of cancers. This practical title by Drs. Fumito Ito and Marc Ernstoff synthesizes the most up-to-date research and clinical guidance available on immune checkpoint inhibitors and presents this information in a compact, easy-to-digest resource. It's an ideal concise reference for trainee and practicing medical oncologists, as well as those in research. - Discusses the current understanding of how to best harness the immune system against different types of cancer at various stages. - Helps you translate current research and literature into practical information for daily practice. - Presents information logically organized by disease site. - Covers tumor immunology and biology; toxicities associated with immune checkpoint inhibitors; and future outlooks. - Consolidates today's available information on this timely topic into one convenient resource. |
| egfr mutation targeted therapy: Perioperative Chemotherapy U. Metzger, F. Largiader, H.-J. Senn, 2012-12-06 One reason for failure to cure solid tumors by surgery appears to be the impossibility of controlling metastases that are present but latent at the time of operation. This failure is a common clinical experience with aggressive neoplasms. but it is not always appreciated in tumors with longer survival times. e. g .• breast and colon cancer. In addition. recent evidence indicates that after resection of a primary tumor micrometas tases from it might be enhanced by suppression of immune and reticu loendothelial functions of the host. Other factors, such as increase of coagulability and stress in the perioperative period, can also promote tumor growth. The development of new metastases might be facilitated by cells forced into the circulation during operative manipulations. Such events could be important for the outcome of treatment and it is suggested that preventive measures should be directed to this systemic component of solid tumors. Radical surgery can reduce the number of tumor cells to a subclinical 3 6 stage (10 to 10 cells) in which chemotherapy might be more effective than in advanced stages. Chemotherapy, on the other hand, might aggravate the surgical morbidity by influencing the wound healing pro cess, by decreasing the immune response, and/or by toxicity to the bone marrow and to the gastrointestinal tract, for example. |
| egfr mutation targeted therapy: Targeted Therapies in Lung Cancer: Management Strategies for Nurses and Practitioners Marianne Davies, Beth Eaby-Sandy, 2019-07-16 This book aims to educate nurses and advanced practice providers (APP’s) about known mutations, availability of targeted therapy and the management of patients with non-small cell lung cancer (NSCLC). It will educate nurses and practitioners about the scope of therapy to assure safe and effective lung cancer treatment. In this era of personalized medicine, nurses and APP’s are responsible for guiding patients from diagnosis through treatment. This starts with the identification of patients that can benefit from these therapies, the key role of biopsy acquisition (ie. what to test, when and how often) and treatment selection based on the mutation identified. Readers will learn about the mechanisms of action, administration, potential adverse side effects and unique management strategies for these targeted agents. Lung cancer continues to be the leading cause of cancer death in the United States and worldwide. Recent advances in the identification of specific oncogenic mutations that drive cancer development, growth and metastasis have led to major paradigm shifts in lung cancer treatment. Sophisticated methods are required to identify specific mutations at the time of diagnosis. This book explains how molecularly targeted therapies have been developed that target these drivers. To date, several tyrosine kinase inhibitors have been approved to target the epidermal growth factor receptor (EGFR), EML4-ALK ,ROS1 and BRAF. Most recently, immune checkpoint inhibitors have been approved with some indication that efficacy may be enhanced for patients who overexpress PD-L1. While some driver mutations have been identified, there is ongoing investigation into additional mutations. In the case of driver mutations, lung cancers will develop resistance to therapy. This book provides nurses and APP’s with the mechanisms of resistance that have been identified such as T790 mutation and many others in the EGFR mutation, and shows how the next level of drug development is focused on identifying mechanisms of resistance and development of new agents that overcome these mutations. With this book in hand, nurses and practitioners will be able to navigate patients through this ever expanding field of lung cancer treatment. |
| egfr mutation targeted therapy: Classification and Regression Trees Leo Breiman, 2017-10-19 The methodology used to construct tree structured rules is the focus of this monograph. Unlike many other statistical procedures, which moved from pencil and paper to calculators, this text's use of trees was unthinkable before computers. Both the practical and theoretical sides have been developed in the authors' study of tree methods. Classification and Regression Trees reflects these two sides, covering the use of trees as a data analysis method, and in a more mathematical framework, proving some of their fundamental properties. |
| egfr mutation targeted therapy: Targeted Therapies in Cancer Marc Lacroix, 2016 Besides surgery, radiation therapy, endocrine therapy or chemotherapy, which were widely used in cancer patients for decades, the 21st century has seen the emergence of targeted therapy, resulting from the identification of molecular pathways in cells and their alterations in tumors. An increasing number of compounds targeting specific molecules or cancer cells have been developed and, for some of them, approved by the United States Food and Drug Administration (FDA) as well as other regulators in EU and Japan Additional new and more efficient types of compounds, are still in clinical trials, but are expected to gain future approval. More than eighty FDA-approved targeted therapies are described here, along with about eighty other promising compounds. These drugs are members of various therapy classes, including tyrosine kinase inhibitors; serine/threonine kinase inhibitors; dual specificity kinase inhibitors; lipid kinase inhibitors; poly ADP ribose polymerase inhibitors; monoclonal antibodies; microtubule targeting agents; histone deacetylase inhibitors; proteasome inhibitors; antimetabolites; immunomodulatory agents; DNA methyltransferase inhibitors; hedgehog pathway inhibitors; enzymes; protein translation inhibitors; vaccines, oncolytic viruses; chimeric antigen receptor T-cells (CAR-T); and so on. A series of companion diagnostics intended to be used as an indication for specific therapies, and approved to this aim are also mentioned. The book aims to present the broad landscape of compounds and companion diagnostics that are expected to pave the way towards a future of hope for cancer patients. |
| egfr mutation targeted therapy: Lung Cancer and Personalized Medicine Aamir Ahmad, Shirish Gadgeel, 2015-12-14 This, the first of two volumes on personalized medicine in lung cancer, touches on the core issues related to the understanding of lung cancer—statistics and epidemiology of lung cancer—along with the incidence of lung cancer in non-smokers. A major focus of this volume is the state of current therapies against lung cancer—immune, targeted therapies against EGFR TKIs, KRAS, ALK, angiogenesis; the associated challenges, especially resistance mechanisms; and recent progress in targeted drug development based on metal chemistry. Chapters are written by some of the leading experts in the field, who provide a better understanding of lung cancer, the factors that make it lethal, and current research focused on developing personalized treatment plans. With a unique mix of topics, this volume summarizes the current state-of-knowledge on lung cancer and the available therapies. |
| egfr mutation targeted therapy: Pocket Oncology Alexander Drilon, Michael Postow, 2014 Pocket Oncology, developed and edited by oncologists at Memorial Sloan-Kettering Cancer Center, is a simple, yet comprehensive, review of basic principles of cancer management. Prepared in the style and format of books in the popular Pocket Notebook series, Pocket Oncology is intended as a quick reference presented in easy to read bulleted text, and using diagrams and charts where appropriate. Each oncologic disease is presented on two facing pages that review initial clinical presentation, pathophysiology, staging, current standard of care treatments, and active areas of current research. Edited by Alexander Drilon and Michael Postow, the content of the book has been written by medical oncology fellows and each disease entity has been authoritatively reviewed by an oncologist with specific expertise in each subspecialty of oncology. Features: -simple, comprehensive, review of basic principles of oncology in easy to read bulleted text, using diagrams and charts where appropriate. -its small size makes it easy to carry the pocket of a lab coat for quick reference to information while in the hospital or oncology clinic. -perfect for medical students, residents, fellows, physician assistants, and nurses who perform daily oncologic care. |
| egfr mutation targeted therapy: Dynamics Of Cancer: Mathematical Foundations Of Oncology Dominik Wodarz, Natalia Komarova, 2014-04-24 The book aims to provide an introduction to mathematical models that describe the dynamics of tumor growth and the evolution of tumor cells. It can be used as a textbook for advanced undergraduate or graduate courses, and also serves as a reference book for researchers. The book has a strong evolutionary component and reflects the viewpoint that cancer can be understood rationally through a combination of mathematical and biological tools. It can be used both by mathematicians and biologists. Mathematically, the book starts with relatively simple ordinary differential equation models, and subsequently explores more complex stochastic and spatial models. Biologically, the book starts with explorations of the basic dynamics of tumor growth, including competitive interactions among cells, and subsequently moves on to the evolutionary dynamics of cancer cells, including scenarios of cancer initiation, progression, and treatment. The book finishes with a discussion of advanced topics, which describe how some of the mathematical concepts can be used to gain insights into a variety of questions, such as epigenetics, telomeres, gene therapy, and social interactions of cancer cells. |
| egfr mutation targeted therapy: Tumor Angiogenesis Assays Domenico Ribatti, 2022-09-26 This second edition provides new and updated methods and protocols for studying tumor angiogenesis in vitro and in vivo. Chapters detail morphological aspects of tumor angiogenesis, aortic ring, ex vivo tissue culture model for anti-angiogenic drug testing, transgenic zebrafish, orthotopic models of ovarian cancer, and uncovering metabolic effects of anti-angiogenic therapy in tumors by induced metabolic bioluminescence imaging.Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Cutting-edge and comprehensive, Tumor Angiogenesis Assays: Methods and Protocols, Second Edition is a valuable resource for all researchers interested in learning more about this important and developing field. |
| egfr mutation targeted therapy: Cancer Evolution Charles Swanton, 2017 Tumor progression is driven by mutations that confer growth advantages to different subpopulations of cancer cells. As a tumor grows, these subpopulations expand, accumulate new mutations, and are subjected to selective pressures from the environment, including anticancer interventions. This process, termed clonal evolution, can lead to the emergence of therapy-resistant tumors and poses a major challenge for cancer eradication efforts. Written and edited by experts in the field, this collection from Cold Spring Harbor Perspectives in Medicine examines cancer progression as an evolutionary process and explores how this way of looking at cancer may lead to more effective strategies for managing and treating it. The contributors review efforts to characterize the subclonal architecture and dynamics of tumors, understand the roles of chromosomal instability, driver mutations, and mutation order, and determine how cancer cells respond to selective pressures imposed by anticancer agents, immune cells, and other components of the tumor microenvironment. They compare cancer evolution to organismal evolution and describe how ecological theories and mathematical models are being used to understand the complex dynamics between a tumor and its microenvironment during cancer progression. The authors also discuss improved methods to monitor tumor evolution (e.g., liquid biopsies) and the development of more effective strategies for managing and treating cancers (e.g., immunotherapies). This volume will therefore serve as a vital reference for all cancer biologists as well as anyone seeking to improve clinical outcomes for patients with cancer. |
| egfr mutation targeted therapy: Diagnosing and Treating Adult Cancers and Associated Impairments National Academies Of Sciences Engineeri, National Academies of Sciences Engineering and Medicine, Health And Medicine Division, Board On Health Care Services, Committee on Diagnosing and Treating Adult Cancers, 2021-11-10 Cancer is the second leading cause of death among adults in the United States after heart disease. However, improvements in cancer treatment and earlier detection are leading to growing numbers of cancer survivors. As the number of cancer survivors grows, there is increased interest in how cancer and its treatments may affect a person's ability to work, whether the person has maintained employment throughout the treatment or is returning to work at a previous, current, or new place of employment. Cancer-related impairments and resulting functional limitations may or may not lead to disability as defined by the U.S. Social Security Administration (SSA), however, adults surviving cancer who are unable to work because of cancer-related impairments and functional limitations may apply for disability benefits from SSA. At the request of SSA, Diagnosing and Treating Adult Cancers and Associated Impairments provides background information on breast cancer, lung cancer, and selected other cancers to assist SSA in its review of the listing of impairments for disability assessments. This report addresses several specific topics, including determining the latest standards of care as well as new technologies for understanding disease processes, treatment modalities, and the effect of cancer on a person's health and functioning, in order to inform SSA's evaluation of disability claims for adults with cancer. |
| egfr mutation targeted therapy: Drug Resistance in Colorectal Cancer: Molecular Mechanisms and Therapeutic Strategies Chi Hin Cho, Tao Hu, 2020-05-27 Drug Resistance in Colorectal Cancer: Molecular Mechanisms and Therapeutic Strategies, Volume Eight, summarizes the molecular mechanisms of drug resistance in colorectal cancer, along with the most up-to-date therapeutic strategies available. The book discusses reasons why colorectal tumors become refractory during the progression of the disease, but also explains how drug resistance occurs during chemotherapy. In addition, users will find the current therapeutic strategies used by clinicians in their practice in treating colorectal cancer. The combination of conventional anticancer drugs with chemotherapy-sensitizing agents plays a pivotal role in improving the outcome of colorectal cancer patients, in particular those with drug-resistant cancer cells. From a clinical point-of-view, the content of this book provides clinicians with updated therapeutic strategies for a better choice of drugs for drug-resistant colorectal cancer patients. It will be a valuable source for cancer researchers, oncologists and several members of biomedical field who are dedicated to better treat patients with colorectal cancer. |
| egfr mutation targeted therapy: Thoracic Tumours W. H. O. Classification WHO Classification of Tumours Editorial Board, 2021-04-21 ****When not purchasing directly from the official sales agents of the WHO, especially at online bookshops, please note that there have been issues with counterfeited copies. Buy only from known sellers and if there are quality issues, please contact the seller for a refund.***** Thoracic Tumoursis the fifth available volume in the fifth edition of the WHO series on the classification of human tumours. This series (also known as the WHO Blue Books) is regarded as the gold standard for the diagnosis of tumours and comprises a unique synthesis of histopathological diagnosis with digital and molecular pathology. These authoritative and concise reference books provide indispensable international standards for anyone involved in the care of patients with cancer or in cancer research, underpinning individual patient treatment as well as research into all aspects of cancer causation, prevention, therapy, and education. What's new in this edition? The fifth edition, guided by the WHO Classification of Tumours Editorial Board, establishes a single coherent cancer classification presented across a collection of individual volumes organized on the basis of anatomical site (digestive system, breast, soft tissue and bone, etc.) and structured in a systematic manner, with each tumour type listed within a taxonomic classification: site, category, family (class), type, and subtype. In each volume, the entities are now listed from benign to malignant and are described under an updated set of headings, including histopathology, diagnostic molecular pathology, staging, and easy-to-read essential and desirable diagnostic criteria. Who should read this book? * Pathologists * Oncologists * Respiratory physicians * Thoracic radiologists * Cancer researchers * Surgeons * Epidemiologists * Cancer registrars This volume: * Prepared by 217 authors and editors * Contributors from around the world * More than 1000 high-quality images * More than 3500 references |
| egfr mutation targeted therapy: European Lung White Book European Respiratory Society (United Kingdom), Robert Loddenkemper, European Lung Foundation, G. J. Gibson, Y. Sibille, 2003-01-01 |
| egfr mutation targeted therapy: World Cancer Report WORLD HEALTH ORGANIZATION: REGIONAL OFFICE FOR EUROPE., 2020 World Cancer Report: Cancer Research for Cancer Prevention is a multidisciplinary publication, with leading international scientists as authors and reviewers. More than 60 different chapters describe multiple aspects of cancer prevention and the research that underpins prevention, focusing on research activity during the past 5 years. Starting with the latest trends in cancer incidence and mortality worldwide, this publication provides wide-ranging insights into cancer prevention based on the known causes of cancer, factors that determine how cancer develops, and the behaviour of different tumour types, and presents a broad scope of interventions to reduce the cancer burden from a global perspective, including addressing inequalities that affect cancer prevention. |
| egfr mutation targeted therapy: IASLC Staging Manual in Thoracic Oncology Ramón Rami-Porta, 2016-11-01 |
| egfr mutation targeted therapy: Molecular Targeted Therapy of Lung Cancer Yuichi Takiguchi, 2017-01-24 This book discusses the latest molecular targeted therapy of lung cancer including its evaluation and future directions. It clearly illustrates the initial dramatic effectiveness of molecular targeted therapy, recurrence of the disease, overcoming the wide variety of resistance mechanisms using new-generation molecular targeted agents and potential novel approaches. It also outlines the increasing necessity for new diagnostic technology and strategies for managing different adverse effects and novel methods for evaluating effectiveness and safety. Edited and authored by opinion leaders, Molecular Targeted Therapy of Lung Cancer provides a comprehensive overview of the disease and its treatments. It is a valuable resource for graduate students, post-doctoral fellows and faculty staff, as well as researchers involved in clinical and translational research on lung cancer, helping promote new ideas for further advances. |
| egfr mutation targeted therapy: Targeted Therapies Daniel Gioeli, 2011-06-02 This volume explores the mechanisms of resistance to targeted therapeutics. The focus is on the cancer cell signaling network, although other mechanisms of resistance including target mutation, and new areas of study such as cancer stem cells are included. Targeted Therapies: Mechanisms of Resistance highlights examples of changes in the signaling network in response to inhibition of a signaling event and underscores the importance in having a mechanistic understanding of the signaling network in cancer for developing effective targeted cancer therapies. Moreover, cutting edge tools to analyze the cell signaling network will be discussed. This includes the leading edge of techniques as well as computational biology and systems theory. This volume provides the reader with both an overview as well as a detailed perspective on the mechanisms of resistance to targeted therapeutics and will be of great value to the oncologist, the physician-scientist treating patients and the translational scientist working on any aspect of targeted therapeutics. |
| egfr mutation targeted therapy: Overcoming Resistance to EGFR Inhibitors in EGFR-Mutant NSCLC Anthony Faber, 2023-01-30 Overcoming Resistance to EGFR Inhibitors in EGFR Mutant NSCLC presents updated information on how EGFR mutant lung cancers evolve to evade EGFR inhibitors, clinical strategies that identify these mechanisms, and how to implement newer therapeutic strategies to combat resistance and improve patient survival. As resistance to EGFR inhibitors is often through re-activation of MEK/ERK and PI3K pathways, or through loss of cell death responses, there is much overlap with resistance to targeted therapies in other paradigms, such as BRAF inhibitors in BRAF mutant melanoma, and HER2 inhibitors in HER2 amplified breast cancer. This book is a valuable resource for cancer researchers, clinicians, graduate students and other members of the biomedical field who are interested in promising treatments for lung cancer. - Presents historical context on how NSCLC and SCLC has been treated, with an emphasis on NSCLC and how the concept of EGFR inhibitors has been implemented - Discusses critical resistant mechanisms seen in the clinic to 1st, 2nd and 3rd generation EGFR inhibitors - Encompasses the current state of affairs in clinical trials to address resistance |
| egfr mutation targeted therapy: Therapeutic Strategies in EGFR Mutant Lung Cancer Yaxiong Zhang, Tomoya Kawaguchi, Wenhua Liang, Yunpeng Yang, 2022-11-03 |
| egfr mutation targeted therapy: Targeted Therapies in Cancer: Francesco Colotta, Alberto Mantovani, 2007-12-05 Billions of dollars are spent every year on research into targeted therapies for cancer. That’s why it’s more than ever crucial for the thousands of scientists working in the field to keep right up to date with the cutting edge. This fascinating collection of material goes a long way to helping them do so, featuring as it does contributions to a crucial international meeting in Italy. The meeting provided a forum for scientists and clinicians working in cancer drug discovery and therapy to share their opinions and experiences. The text here offers readers an overview of diverse approaches, ranging from drug discovery to cellular therapy. Overall, the book addresses the key question of whether ultimately targeted therapy in cancer will be a myth or a reality. |
| egfr mutation targeted therapy: Targeted Therapies for Lung Cancer Ravi Salgia, 2019-06-26 This book contextualizes translational research and provides an up to date progress report on therapies that are currently being targeted in lung cancer. It is now well established that there is tremendous heterogeneity among cancer cells both at the inter- and intra-tumoral level. Further, a growing body of work highlights the importance of targeted therapies and personalized medicine in treating cancer patients. In contrast to conventional therapies that are typically administered to the average patient regardless of the patient’s genotype, targeted therapies are tailored to patients with specific traits. Nonetheless, such genetic changes can be disease-specific and/or target specific; thus, the book addresses these issues manifested in the somatically acquired genetic changes of the targeted gene. Each chapter is written by a leading medical oncologist who specializes in thoracic oncology and is devoted to a particular target in a specific indication. Contributors provide an in-depth review of the literature covering the mechanisms underlying signaling, potential cross talk between the target and downstream signaling, and potential emergence of drug resistance. |
| egfr mutation targeted therapy: Guide to Targeted Therapies: Treatment Resistance in Lung Cancer Federico Cappuzzo, 2015-10-15 This text is a concise and up-to-date review, which discusses the background, development and mechanisms of resistance, testing methods and technology, current and emerging therapies and resources that clinicians can provide to their patients. Busy healthcare professionals who want a quick review of treatment resistance in lung cancer as well as a summary of current therapies will benefit from this succinct guide. |
Estimated Glomerular Filtration Rate (eGFR) - The National Kidney ...
Jul 13, 2022 · Learn about eGFR, how your kidneys filter waste, and why early detection of CKD is crucial for protecting kidney health. Your kidneys filter your blood by removing waste and …
Estimated Glomerular Filtration Rate (eGFR) - Cleveland Clinic
May 28, 2025 · Healthcare providers use estimated glomerular filtration rate (eGFR) to determine if you have kidney damage and stage kidney disease. eGFR measures your kidneys’ ability to …
Blood test: eGFR (estimated glomerular filtration rate)
Jan 3, 2025 · eGFR (estimated glomerular filtration rate) is a measure of how well your kidneys are working. Your eGFR is an estimated number based on a blood test and your age, sex, and …
Stages of Kidney Disease: 1–5 Listed by eGFR - Verywell Health
Nov 19, 2023 · Chronic kidney disease (CKD) is divided into five stages, ranging from stage 1 to stage 5. Each stage is determined by a blood test known as the estimated glomerular filtration …
Estimated Glomerular Filtration Rate (GFR) Test for Your Kidneys …
Mar 12, 2024 · The glomerular filtration rate (GFR) is a measure of how well your kidneys are removing waste from your blood, which can be determined using an estimated GFR (eGFR) …
MDRD GFR Equation - MDCalc
The MDRD GFR Equation estimates glomerular filtration rate based on creatinine and patient characteristics.
eGFR (Glomerular Filtration Rate) Test + How To Improve
Jan 20, 2021 · eGFR is a measure of how well your kidneys are working. It is often reported automatically when you do a creatinine blood test, as a part of your comprehensive metabolic …
100768: Glomerular Filtration Rate, Estimated (eGFR) - Labcorp
The estimated glomerular filtration rate (eGFR) provides an assessment of the filtering capacity of the kidney. Measuring serum creatinine along with an estimated glomerular filtration rate …
What Does It Mean If eGFR Is High? - MedicineNet
Glomerular filtration rate (GFR) is a marker of kidney health. Learn the normal range of eGFR, the purposes of the test, and how to interpret the results.
Estimated Glomerular Filtration Rate (eGFR) - Patient
Feb 9, 2023 · The eGFR is a test that is used to assess how well your kidneys are working. The test estimates the volume of blood that is filtered by your kidneys over a given period of time. …
Estimated Glomerular Filtration Rate (eGFR) - The National Kidney ...
Jul 13, 2022 · Learn about eGFR, how your kidneys filter waste, and why early detection of CKD is crucial for protecting kidney health. Your kidneys filter your blood by removing waste and …
Estimated Glomerular Filtration Rate (eGFR) - Cleveland Clinic
May 28, 2025 · Healthcare providers use estimated glomerular filtration rate (eGFR) to determine if you have kidney damage and stage kidney disease. eGFR measures your kidneys’ ability to …
Blood test: eGFR (estimated glomerular filtration rate)
Jan 3, 2025 · eGFR (estimated glomerular filtration rate) is a measure of how well your kidneys are working. Your eGFR is an estimated number based on a blood test and your age, sex, and …
Stages of Kidney Disease: 1–5 Listed by eGFR - Verywell Health
Nov 19, 2023 · Chronic kidney disease (CKD) is divided into five stages, ranging from stage 1 to stage 5. Each stage is determined by a blood test known as the estimated glomerular filtration …
Estimated Glomerular Filtration Rate (GFR) Test for Your Kidneys …
Mar 12, 2024 · The glomerular filtration rate (GFR) is a measure of how well your kidneys are removing waste from your blood, which can be determined using an estimated GFR (eGFR) …
MDRD GFR Equation - MDCalc
The MDRD GFR Equation estimates glomerular filtration rate based on creatinine and patient characteristics.
eGFR (Glomerular Filtration Rate) Test + How To Improve
Jan 20, 2021 · eGFR is a measure of how well your kidneys are working. It is often reported automatically when you do a creatinine blood test, as a part of your comprehensive metabolic …
100768: Glomerular Filtration Rate, Estimated (eGFR) - Labcorp
The estimated glomerular filtration rate (eGFR) provides an assessment of the filtering capacity of the kidney. Measuring serum creatinine along with an estimated glomerular filtration rate …
What Does It Mean If eGFR Is High? - MedicineNet
Glomerular filtration rate (GFR) is a marker of kidney health. Learn the normal range of eGFR, the purposes of the test, and how to interpret the results.
Estimated Glomerular Filtration Rate (eGFR) - Patient
Feb 9, 2023 · The eGFR is a test that is used to assess how well your kidneys are working. The test estimates the volume of blood that is filtered by your kidneys over a given period of time. …
